Canada’s Drug Agency Receives Letter From Health Minister Regarding Pharmacare

Canada’s Drug Agency has received a letter from The Honourable Mark Holland that outlines our time-limited work related to An Act respecting pharmacare, which received royal assent on October 10, 2024.

We have begun to undertake the work outlined in the legislation and the letter, building on our mandate to provide health system leaders with independent evidence and advice to inform policy decisions about drugs, health technologies, and health systems.

We’ll continue to collaborate with the provincial, territorial, and federal governments, Indigenous Peoples and organizations, patients and communities, clinicians, and other interested parties to drive better coordination, alignment, and public value within the drug and health technology landscape in Canada.

Information regarding this work will be communicated as it becomes available.